Drugs / Pemziviptadil
Pemziviptadil
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01873885 | Jun 2013 → Mar 2014 | essential hypertension | PhaseBio Pharmaceuticals Inc. | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT04433546 | Jul → Dec 2020 | COVID-19, acute respiratory distress syndrome, cytokine release syndrome, heart failure +3 | PhaseBio Pharmaceuticals Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT03795428 | Apr 2019 → Jan 2022 | pulmonary arterial hypertension | PhaseBio Pharmaceuticals Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT03556020 | Jul 2018 → Jan 2022 | pulmonary arterial hypertension | PhaseBio Pharmaceuticals Inc. | Terminated | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT01523067 Comparator | Jan → Dec 2012 | essential hypertension | PhaseBio Pharmaceuticals Inc. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pemziviptadil | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03556020 ↗ |
| Known as | PB1046 | “This is a multi-center, Phase 2 Long-Term, Open Label Extension (OLE) Study to assess the safety and tolerability of pemziviptadil (PB1046) at an optimally titrated dose.” NCT03795428 ↗4“Pemziviptadil (PB1046) is expected to improve the clinical outcomes of hospitalized COVID-19 subjects with an earlier hospital discharge and improvement in survival.” NCT04433546 ↗ “Drug: Pemziviptadil (PB1046), Once Weekly Subcutaneous Injection” NCT03556020 ↗ “Experimental: Single IV Infusion Vasomera (PB1046)” NCT01873885 ↗ “Vasomera (PB1046)” NCT01523067 ↗ |
| Known as | Vasomera | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01523067 ↗ |
| Modality | Peptide | “Sustained-Release Vasoactive Intestinal Peptide (VIP) Analogue” NCT03556020 ↗ |
| Route | Subcutaneous | “administered subcutaneously” NCT01523067 ↗ |